miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in or...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomed Res Int
Main Authors: Merhautova, Jana, Hezova, Renata, Poprach, Alexandr, Kovarikova, Alena, Radova, Lenka, Svoboda, Marek, Vyzula, Rostislav, Demlova, Regina, Slaby, Ondrej
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433647/
https://ncbi.nlm.nih.gov/pubmed/26064968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/941980
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados